Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen M?ller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.
Clinical Trials
4
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2008
Active, not recruiting
2
50.0%
Recruiting
1
25.0%
Terminated
1
25.0%
No approval data available
• ExpreS2ion Biotech secured crucial approval for Phase I clinical trial of ES2B-C001, their novel HER2-expressing breast cancer therapeutic vaccine, marking their entry into clinical development. • The company's collaboration with University of Oxford yielded positive Phase 2b malaria vaccine results, published in The Lancet Infectious Diseases, showing promise in meeting WHO's 75% efficacy goal. • ExpreS2ion strengthened its financial position through successful TO 10 warrants exercise, raising approximately SEK 10 million, while maintaining a cash balance of SEK 81.5 million by end of 2024.
- Evaxion Biotech has completed dosing in its Phase 2 trial of EVX-01, a personalized cancer vaccine, for advanced melanoma treatment. - The trial evaluates EVX-01 in combination with MSD’s Keytruda (pembrolizumab), with each patient receiving a uniquely designed vaccine. - Interim data from the Phase 2 trial presented at ESMO 2024 showed a 69% overall response rate and a positive correlation between AI predictions and immune responses. - The company anticipates a full clinical data readout in the second half of 2025, with hopes that EVX-01 could become a new treatment option.
- Evaxion Biotech utilizes its AI platform, AI Immunology, for rapid vaccine discovery and development, targeting cancer and infectious diseases. - The company's lead candidate, EVX-01, a personalized neoantigen vaccine, demonstrated a 69% overall response rate in a Phase II trial for metastatic melanoma. - Evaxion's EVX-B2 vaccine against gonorrhea showed pre-clinical proof of concept in an mRNA construct, confirming the platform's delivery modality-agnostic nature. - Aiming for financial sustainability, Evaxion targets business development income equal to its $14 million annual cash burn in 2024 through strategic partnerships.
- Evaxion Biotech's AI-Immunology™ platform demonstrates strong ability to select clinically relevant vaccine targets across three clinical trials. - Top-ranked AI-Immunology™ vaccine targets correlate with the strongest clinical outcomes, linking AI-driven design with real-world evidence. - The platform's predictive precision improved significantly, with 79% of predicted targets in the EVX-01 phase 2 trial triggering a tumor-specific immune response. - Clinical data enables continuous refinement of AI-Immunology™, broadening the platform's commercial potential in personalized cancer vaccine development.
